Precigen stock
PGENNASDAQPrecigen, Inc., HealthcareISIN US74017N1054
54Score 54 out of 100, Neutral
Price and trend
47 / 100
Price history
+16% in one yearThe chart shows daily closes over 13 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 12% below it.
Since May 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 35).
The price is 46% below its 52-week high. Largest decline in 13 years: 99% (August 2015 to December 2024).
Chart figures for advanced users
- SMA 50$6.79
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.28
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)35
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.10
- The lowest closing price of the last twelve months.
- Resistance$8.56
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Precigen, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.67B, is number 144 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $9.68M (up 146.7% year on year) and a loss of $250.64M.
- MEQIRI Score 54 out of 100 (Neutral): rank 342 of 702 in Healthcare, median 53.
Show more
- Our model puts fair value at $8.00, with the price 42% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 42% below the fair value of $8.00.
- High marginNet margin 15.6% over the last 12 months, Biotechnology median −103.7%.Profitability 91
Weaknesses
- DilutionShare count up 82% since 2020.Capital allocation 54
- Volatile share priceVolatility 85% a year over the last 12 months.Stability 40
- Negative free cash flowFree cash flow −$74.92M over the last 12 months.Fundamentals 40
Its standout strength is profitability, while fundamentals and stability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 55 to 54.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- price far below its 52-week high
- weak fundamentals
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $5.33 and expensive above $16.00 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $14.74 (cash-flow model) and $1.26 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.4%. At 10.4% the fair value would be $7.11, at 8.4% it would be $9.26.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 147% on the prior year. Revenue has grown strongly since 2023, at around 25% per year. From 2023 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 37%, operating −1101%, net −2588%. Last 12 months: net 16%. From 2023 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Mar 2027in 131 days
- Last reported
- 4 Nov 2026EPS reported $0.08 (expected $0.06)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 37.1% since 15 Oct 2026.
- Earnings per share
- $0.24+37.1%
- Revenue
- $242.41M+1.5%
- Earnings per share
- $0.62−2.8%
- Revenue
- $446.34M+0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +4.2%Funding through cash flow breakeven by the end of 2026 reiterated; continued growth for PAPZIMEOS expected.
“We continue to reiterate that based on our current financial forecast, our cash, cash equivalents and investments, along with the collection of PAPZIMEOS receivables will fund operations through cash flow breakeven by the end of 2026.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $24,662 in total. 6 insiders sold, $7.95M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Kindler Jeffrey BSale
26 Aug 2026, Board
- Shares
- 185,000
- Price
- $7.44
- Value
- $1.38M
- Shah Rutul RSale
25 Aug 2026, Chief Operating Officer
- Shares
- 15,342
- Price
- $7.50
- Value
- $115,065
- Tennant PhilSale
25 Aug 2026, Chief Commercial Officer
- Shares
- 79,166
- Price
- $7.50
- Value
- $593,745
Show 14 more
- Agee Nancy HPurchase
21 Aug 2026, Board
- Shares
- 3,411
- Price
- $7.23
- Value
- $24,662
- Shah Rutul RSale
21 Aug 2026, Chief Operating Officer
- Shares
- 34,658
- Price
- $7.50
- Value
- $259,935
- Shah Rutul RSale
6 Aug 2026, Chief Operating Officer
- Shares
- 32,739
- Price
- $6.86
- Value
- $224,590
- Shah Rutul RSale
3 Aug 2026, Chief Operating Officer
- Shares
- 33,772
- Price
- $6.50
- Value
- $219,518
- Thomasian Harry Jr.Sale
31 Jul 2026, Chief Financial Officer
- Shares
- 100,000
- Price
- $6.06
- Value
- $606,000
- Thomasian Harry Jr.Sale
1 Jul 2026, Chief Financial Officer
- Shares
- 171,429
- Price
- $5.53
- Value
- $948,002
- Thomasian Harry Jr.Sale
29 Jun 2026, Chief Financial Officer
- Shares
- 28,571
- Price
- $5.78
- Value
- $165,140
- Shah Rutul RSale
29 Jun 2026, Chief Operating Officer
- Shares
- 42,924
- Price
- $5.85
- Value
- $251,105
- Sabzevari HelenSale
29 Jun 2026, President and CEO
- Shares
- 346,836
- Price
- $5.89
- Value
- $2.04M
- Thomasian Harry Jr.Sale
28 May 2026, Chief Financial Officer
- Shares
- 41,884
- Price
- $4.36
- Value
- $182,614
- Tennant PhilSale
28 May 2026, Chief Commercial Officer
- Shares
- 30,272
- Price
- $4.36
- Value
- $131,986
- Shah Rutul RSale
28 May 2026, Chief Operating Officer
- Shares
- 42,703
- Price
- $4.36
- Value
- $186,185
- Lehr Donald P.Sale
28 May 2026, Chief Legal Officer
- Shares
- 29,131
- Price
- $4.36
- Value
- $127,011
- Sabzevari HelenSale
28 May 2026, President and CEO
- Shares
- 119,250
- Price
- $4.36
- Value
- $519,930
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Precigen
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 54
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Stoke TherapeuticsSTOK $1.71B37
- Taysha Gene TherapiesTSHA $1.71B35
- Nurix TherapeuticsNRIX $1.7B68
- MesoblastMESO $1.7B37
- Ultragenyx PharmaceuticalRARE $1.66B38
- NanobiotixNANO.PA $1.64B38
- SELLAS Life Sciences GroupSLS $1.62B35
- Generate BiomedicinesGENB $1.61B36
ETFs that hold Precigen
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.10% | 0.35% | €1.25B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.22B |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.5B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.54B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €178.55M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.84B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Nov 2026)
- Valuation signal Undervalued since 12 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.